Multi-institutional retrospective observational study on the epidemiology of oligo disease and the significance of local therapy in advanced or recurrent thymic carcinoma (NEJ070)

Multi-institutional retrospective observational study on the epidemiology of oligo disease and the significance of local therapy in advanced or recurrent thymic carcinoma (NEJ070) - NEJ070

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060321

Enrollment

400

Registered

2026-01-13

Start date

2026-01-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thymic carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria will be included in the study 1) Thymic carcinoma confirmed by histological diagnosis. 2) Unresectable Masaoka stage III or higher disease, or recurrence after surgical resection and/or definitive (chemo)radiotherapy. 3) Advanced or recurrent disease diagnosed between April 1, 2000 and December 31, 2023. 4) Receipt of at least one of the following treatments: local therapy (palliative surgery or radiotherapy) and/or systemic chemotherapy.

Exclusion criteria

Exclusion criteria: Patients who meet any of the following criteria will be excluded from the study; 1) Cases deemed inappropriate for inclusion by the researchers.

Design outcomes

Primary

Measure	Time frame
Epidemiological assessment 1) The prevalence of oligometastatic disease in patients with advanced or recurrent thymic carcinoma, as well as patterns of metastasis (metastatic organs and number of metastatic lesions) 2) The frequency and types of local therapy administered for oligometastatic disease Prognostic evaluation Overall survival (comparison between patients who received local therapy and those who did not)	—

Measure

Time frame

Epidemiological assessment 1) The prevalence of oligometastatic disease in patients with advanced or recurrent thymic carcinoma, as well as patterns of metastasis (metastatic organs and number of metastatic lesions) 2) The frequency and types of local therapy administered for oligometastatic disease Prognostic evaluation Overall survival (comparison between patients who received local therapy and those who did not)

—

Secondary

Measure	Time frame
Efficacy and safety of first line treatment Progression free survival (PFS), objective response rate (ORR), disease control rate (DCR), and incidence of adverse events In patients who underwent local therapy Efficacy and safety of local therapy PFS, ORR, DCR, and incidence of adverse events Efficacy and safety of systemic therapy before and after local therapy PFS, ORR, DCR, and incidence of adverse events	—

Measure

Time frame

Efficacy and safety of first line treatment Progression free survival (PFS), objective response rate (ORR), disease control rate (DCR), and incidence of adverse events In patients who underwent local therapy Efficacy and safety of local therapy PFS, ORR, DCR, and incidence of adverse events Efficacy and safety of systemic therapy before and after local therapy PFS, ORR, DCR, and incidence of adverse events

—

Countries

Japan

Contacts

Public ContactShunichi Kataoka

Shizuoka Cancer Center Division of Thoracic Oncology

s-kataoka@juntendo.ac.jp055-989-5222

Outcome results